title: [Developments in HPV vaccination].
abstract: Vaccination against the human papilloma virus (HPV) has been included in the national Vaccination Programme of the Netherlands for 12-year-old girls since 2010. Vaccination coverage for the birth cohort of 1997 was 56.; there is a gradual increase in uptake. Continuous safety monitoring brought no new unknown serious side effects to light; many girls suffered from transient symptoms such as painful arm, fatigue and headache. After the current vaccines that protect against HPV types 2 and 4 types, respectively and induce some cross protection, vaccines are being developed that can induce broader protection. HPV vaccination of 12-year-old girls is cost-effective, even for relatively low vaccination coverage. The potential protection of HPV vaccination extends beyond prevention of cervical cancer by preventing other oncological manifestations of HPV infection in women as well as men and genital warts. The preventive HPV vaccines do not appear to be effective in treating existing abnormalities.
authors.affiliation: Centrum Infectieziektebestrijding, RIVM, Bilthoven, the Netherlands.
authors.forename: Hester
authors.initials: H
authors.lastname: de Melker
authors.forename: Gemma
authors.initials: G
authors.lastname: Kenter
authors.forename: Tekla
authors.initials: T
authors.lastname: van Rossum
authors.forename: Marina
authors.initials: M
authors.lastname: Conyn-van Spaendonck
mesh_terms: D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D030361:Papillomavirus Infections / Q000191:economics / Q000517:prevention & control* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000191:economics / Q000276:immunology*; D002577:Uterine Cervical Diseases / Q000191:economics / Q000517:prevention & control* / Q000821:virology; D002583:Uterine Cervical Neoplasms / Q000191:economics / Q000517:prevention & control* / Q000821:virology
chemical_list: D053918:Papillomavirus Vaccines